Developing and Testing Warning Labels for Retail Cannabis Products

开发和测试零售大麻产品的警告标签

• 批准号: 10738445
• 负责人: Zachary Massey
• 金额: $ 16.17万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10738445
• 关键词: Adult; Affect; Attitude; Automobile Driving; Behavioral; Belief; Biological; Cancer Patient; Cannabis; Cannabis policy; Cannabis retail; Cardiovascular Diseases; Characteristics; Colorado; Consumption; Data; Development; Emotions; Ensure; Environment; Focus Groups; Future; Goals; Health; Health behavior; Impaired cognition; Intervention; Label; Learning; Legal; Literature; Lung diseases; Measures; Mentorship; Methods; Motivation; Nausea; Outcome; Outcome Study; Participant; Patient Recruitments; Perception; Poison Control Centers; Policies; Population; Product Labeling; Provider; Psychoses; Reaction; Recreation; Regulation; Reporting; Research; Research Activity; Research Methodology; Risk; Science; Scientist; Social Marketing; Source; Testing; Text; Therapeutic; Time; Tobacco Control Research; Training; Training Activity; Translating; Update; Variant; Work; addiction; adverse outcome; behavior influence; cannabis use behavior; career; design; drugged driving; experience; experimental study; follow-up; health belief; health communication; health knowledge; health warning; high risk; improved; innovation; insight; marijuana legalization; marijuana use; multiple sclerosis patient; novel; programs; psychologic; randomized, clinical trials; respiratory; risk perception; smoking cessation; spasticity; substance use; theories; therapy outcome; warning label

PROJECT ABSTRACT Despite the legalization of retail cannabis (i.e., non-medical, “recreational”) in multiple states, there are still no federal regulations for warnings on cannabis products in the U.S. This is troubling because states that legalize cannabis report increased calls to poison control centers, and cannabis consumption has been associated with cognitive impairment, deadly lung disease, and respiratory problems. At the same time, cannabis has therapeutic benefits, including reduced spasticity for multiple sclerosis patients. The fact that cannabis has adverse and therapeutic outcomes has contributed to an environment where substantial proportions of U.S. consumers both over- and under-estimate the health risks of cannabis. This highlights the need for clear, effective labeling regulations to ensure accurate risk perceptions. Despite evidence of the efficacy of health warning attributes (e.g., adding pictures to text), there is limited data on how such warning attributes influence cannabis consumers in the U.S. This proposal will inform how cannabis warning-label characteristics influence cannabis consumers’ (i.e., past 30-day use) attitudes and beliefs, intentions, and problematic cannabis use behaviors by accomplishing the following specific aims: Aim 1: Assess consumer perceptions about draft cannabis warning labels through focus groups with adult cannabis consumers (21+) from legal retail states; Aim 2: Determine how attributes of updated cannabis warning labels affect cannabis consumers’ (21+ from retail states) emotions and perceived risk using a discrete choice experiment (DCE); Aim 3: Use a randomized clinical trial (RCT) to test enhanced warning labels against the existing product labels to determine how exposure influences cannabis consumers’ (21+ from retail states) label reactions (emotion and reactance), attitudes and beliefs (perceived risks and health beliefs about cannabis), and intentions for problematic use (e.g., driving after cannabis consumption) immediately after exposure (Session 1). At 2-week follow-up (Session 2), we will measure message recall and cannabis-use behaviors in the last 2 weeks (i.e., interpersonal conversations about cannabis, cannabis use, money spent on cannabis, quitting attempts, and problematic use), and behavioral intentions (motivation to quit cannabis in 6 months). This innovative proposal includes training activities to ensure that Dr. Massey achieves the following five career goals: 1) Develop expertise in psychological and biological mechanisms of addiction; 2) Receive hands-on training for the development of cannabis warning labels; 3) Learn advanced research methods for warning label research with DCEs; 4) Acquire advanced training in RCTs; and 5) Create a sustainable line of research for future R01 submissions. The mentorship team includes experts in developing and testing warning labels (Hammond, Thrasher, Popova), substance use research (Hammond, Froeliger), cannabis policy (Hammond), mixed methods (Popova, Rodgers, Thrasher), and design of DCEs and RCTs to test consumer warnings (entire team). The proposed mentorship, training, and research activities would prepare Dr. Massey for an independent research career with a sustainable substance-use research program.

项目摘要 尽管零售大麻合法化（即，非医疗，“娱乐”）在多个州，仍然有 在美国，没有关于大麻产品警告的联邦法规。 大麻报告增加了对毒物控制中心的呼叫，大麻消费与 认知障碍致命的肺病和呼吸系统疾病与此同时，大麻具有治疗作用， 好处，包括减少多发性硬化症患者的痉挛。事实上，大麻有不利的， 治疗结果促成了一种环境，其中相当大比例的美国消费者 高估和低估大麻的健康风险。这突出表明需要明确、有效的标签 以确保准确的风险认知。尽管有证据表明健康警告属性的功效 (e.g.,在文本中添加图片），但关于此类警告属性如何影响大麻消费者的数据有限 这项提案将告知大麻警告标签特征如何影响大麻消费者的消费。 (i.e.,过去30天的使用）的态度和信念，意图，以及有问题的大麻使用行为， 实现以下具体目标：目标1：评估消费者对大麻警告草案的看法 通过与来自法律的零售州的成年大麻消费者（21岁以上）的焦点小组进行标签;目标2：确定如何 更新的大麻警告标签的属性影响大麻消费者（来自零售州的21岁以上）的情绪， 使用离散选择实验（DCE）的感知风险;目的3：使用随机临床试验（RCT）来检验 加强对现有产品标签的警告标签，以确定接触如何影响大麻 消费者（21+来自零售州）的标签反应（情绪和反应），态度和信仰（感知 关于大麻的风险和健康信念），以及有问题使用的意图（例如，吸食大麻后驾车 暴露后立即服用（第1阶段）。在2周随访时（第2阶段），我们将测量 最近2周内的消息回忆和大麻使用行为（即，人际对话关于 大麻，大麻使用，大麻上花的钱，戒烟尝试和有问题的使用），以及行为 意图（在6个月内戒烟的动机）。这一创新建议包括培训活动，以确保 梅西博士实现了以下五个职业目标：1）发展心理和生物学方面的专业知识 2）接受制定大麻警告标签的实践培训; 3）学习 与DCE一起进行警告标签研究的先进研究方法; 4）获得RCT的高级培训;以及 5)为未来的R 01提交创建可持续的研究路线。指导小组包括以下方面的专家： 开发和测试警告标签（哈蒙德，Thrasher，波波娃），物质使用研究（哈蒙德， Froeliger），大麻政策（哈蒙德），混合方法（波波娃，罗杰斯，Thrasher），以及DCE和 RCT测试消费者警告（整个团队）。拟议的指导、培训和研究活动将 准备梅西博士的独立研究生涯与可持续的物质使用研究计划。